Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

The US Food and Drug Administration (FDA) has approved a drug for schizophrenia that is exciting the field with an entirely ...

Home-based phototherapy for plaque and guttate psoriasis is as effective as office-based phototherapy, results of the ...

The Centers for Medicare & Medicaid Services (CMS) has added several changes to the Medicare price negotiation process ...

By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...

North America Cancer Immunotherapy Market is expanding rapidly due to expanding approval of immunotherapeutic drugs for the treatment of increasing incidences of cancer and increasing investments in ...